Responses
Regular and young investigator award abstracts
Clinical trials completed
285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
